BidaskClub downgraded shares of PAREXEL International Corporation (NASDAQ:PRXL) from a strong-buy rating to a buy rating in a research note released on Friday morning.

Several other equities analysts have also recently commented on the stock. Jefferies Group LLC reissued a hold rating and set a $88.10 target price on shares of PAREXEL International Corporation in a research report on Wednesday, June 21st. Barclays PLC cut shares of PAREXEL International Corporation from an overweighr rating to an equal weight rating and set a $87.00 target price on the stock. in a research report on Tuesday, June 20th. Raymond James Financial, Inc. raised shares of PAREXEL International Corporation from an underperform rating to a mkt perform rating in a research report on Tuesday, June 20th. Credit Suisse Group reissued a neutral rating and set a $83.00 target price (up previously from $65.00) on shares of PAREXEL International Corporation in a research report on Tuesday, June 6th. Finally, Mizuho lifted their target price on shares of PAREXEL International Corporation from $66.00 to $75.00 and gave the stock a buy rating in a research report on Tuesday, May 30th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. PAREXEL International Corporation has an average rating of Hold and a consensus target price of $74.70.

Shares of PAREXEL International Corporation (PRXL) traded down 0.08% during trading on Friday, reaching $87.45. The company’s stock had a trading volume of 177,022 shares. The firm has a market cap of $4.44 billion, a PE ratio of 38.44 and a beta of 0.79. The stock’s 50 day moving average price is $86.52 and its 200-day moving average price is $72.94. PAREXEL International Corporation has a 12 month low of $51.16 and a 12 month high of $87.86.

PAREXEL International Corporation (NASDAQ:PRXL) last posted its earnings results on Wednesday, May 3rd. The medical research company reported $0.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. PAREXEL International Corporation had a net margin of 5.12% and a return on equity of 28.68%. The firm had revenue of $529.30 million for the quarter, compared to analysts’ expectations of $529.38 million. During the same quarter last year, the firm earned $0.89 EPS. The company’s quarterly revenue was up .4% compared to the same quarter last year. Equities analysts predict that PAREXEL International Corporation will post $3.24 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/parexel-international-corporation-prxl-cut-to-buy-at-bidaskclub/1465618.html.

Several large investors have recently modified their holdings of PRXL. Public Employees Retirement System of Ohio raised its position in PAREXEL International Corporation by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock worth $108,000 after buying an additional 73 shares in the last quarter. Meadow Creek Investment Management LLC raised its position in PAREXEL International Corporation by 7.1% in the first quarter. Meadow Creek Investment Management LLC now owns 1,980 shares of the medical research company’s stock worth $125,000 after buying an additional 132 shares in the last quarter. Invictus RG acquired a new position in PAREXEL International Corporation during the first quarter worth $158,000. Glen Harbor Capital Management LLC raised its position in PAREXEL International Corporation by 7.1% in the first quarter. Glen Harbor Capital Management LLC now owns 2,520 shares of the medical research company’s stock worth $159,000 after buying an additional 168 shares in the last quarter. Finally, Elkfork Partners LLC raised its position in PAREXEL International Corporation by 7.1% in the first quarter. Elkfork Partners LLC now owns 3,060 shares of the medical research company’s stock worth $193,000 after buying an additional 204 shares in the last quarter. Institutional investors own 95.90% of the company’s stock.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Analyst Recommendations for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.